Spotlight on brexpiprazole and its potential in the treatment of schizophrenia and as adjunctive therapy for the treatment of major depression

References

• TandonRAntipsychotics in the treatment of schizophrenia: an overviewJ Clin Psychiatry20117218
   Web of Science ®Google Scholar
• MaedaKSuginoHAkazawaHBrexpiprazole I: in-vitro and in-vivo characterization of a novel serotonin-dopamine activity modulatorJ Pharmacol Exp. Ther201435058960424947465
   PubMed Web of Science ®Google Scholar
• TandonRMollerH-JBelmakerRHWorld Psychiatry Association Pharmacopsychiatry Section statement on comparative effectiveness of antipsychotics in the treatment of schizophreniaSchizophr Res2008100203818243663
   PubMed Web of Science ®Google Scholar
• KapurSRemingtonGDopamine D2 receptors and their role in antipsychotic action: still necessary and may even be sufficientBiol Psychiatry20015087388311743942
   PubMed Web of Science ®Google Scholar
• OosterhofCAEl MansariMBlierPAcute effects of brexpiprazole on serotonin, dopamine, and norepinephrine systems: an in-vivo electrophysiologic characterizationJ Pharmacol Exp Ther201435158559525225185
   PubMed Web of Science ®Google Scholar
• TandonRNasrallahHAKeshavanMSSchizophrenia, “Just the facts” 5. Treatment and preventionSchizophr Res201012212320655178
   PubMed Web of Science ®Google Scholar
• YoshimiNFujitaYOhgiYFutamuraTKikuchiTHashimotoKEffects of brexpiprazole, a novel serotonin-dopamine modulator, on phencyclidine-induced cognitive deficits in mice: a role for 5HT1A receptorsPharmacol Biochem Behav201412424524924955861
   PubMed Web of Science ®Google Scholar
• IshimaTFutamuraTOhgiYYoshimiNKikuchiTHashimotoKPotentiation of neurite growth by brexpiprazole, a novel serotonin-dopamine activity modulatorEur Neuropsychopharmaol201525506511
   Web of Science ®Google Scholar
• HimmelochSTaylorSFGoldmanRSTandonRFrontal lobe tasks, antipsychotic medication, and schizophrenia syndromesBiol Psychiatry1996392272298837987
   PubMed Web of Science ®Google Scholar
• YoshimiNFutamuraTHashimotoKImprovement of dizocilpine-induced social recognition deficits in mice by brexpiprazole, a novel serotonin-dopamine activity modulatorEur Neuropsychopharmaol201525356364
   PubMed Web of Science ®Google Scholar
• TandonRCholinergic aspects of schizophreniaBr J Psychiatry Suppl199917371110211133
   PubMedGoogle Scholar
• OtsukaRexulti (brexpiprazole) Tablets for Oral Use. Prescribing information, 2015 Available from: http://www.otsuks-us.com/products/documents/Rexulti.pdf
   Google Scholar
• McQuadeRHobartMForbesRAA phase II trial assessing the efficacy and safety of OPC-34712 in the acute treatment of schizophreniaPoster presented at: the 24th annual US Psychiatric and Mental Health Congress2011Las Vegas
   Google Scholar
• CorrellCUSkubanAOuyangJEfficacy and safety of brexpiprazole for the treatment of acute schizophrenia: a 6-week randomized, double-blind, placebo-controlled trialAm J Psychiatry201517287088025882325
   PubMed Web of Science ®Google Scholar
• KaneJMSkubanAOuyangJA multi-center, randomized, double-blind, controlled phase 3 trial of fixed-dose brexpiprazole for the treatment of adults with acute schizophreniaSchizophr Res201516412713525682550
   PubMed Web of Science ®Google Scholar
• MarderSRSkubanAOuyangJEfficacy of brexpiprazole on PANSS items and Marder factor scores: a meta-analysis of two pivotal studies in schizophreniaPoster presented at: the 168th annual meeting of the American Psychiatric Association2015Toronto
   Google Scholar
• HobartMOuyangJForbesRAEfficacy and safety of brexpiprazole as maintenance treatment in adults with schizophrenia: a randomized, double-blind, placebo-controlled studyPoster presented at: the annual meeting of the American Society of Psychopharmacology2015Miami
   Google Scholar
• TandonRCucchiaroJPhillipsDA double-blind, placebo-controlled, randomized, withdrawal study of lurasidone for the maintenance of efficacy in patients with schizophreniaJ Psychopharmacology20163016977
   PubMed Web of Science ®Google Scholar
• MaedaKLerdrupLSuginoHBrexpiprazole II: antipsychotic and pro-cognitive effects of a novel serotonin-dopamine activity modulatorJ Pharmacol Exp Ther201435060561424947464
   PubMed Web of Science ®Google Scholar
• TandonRTargumSDNasrallahHARossRTreatment Effectiveness in Schizophrenia Consortium. Strategies for maximizing clinical effectiveness in the treatment of schizophreniaJ Psychiatr Pract20061234836317122696
   PubMedGoogle Scholar
• ThaseMEFavaMHobartMEfficacy of adjunctive OPC-34712 across multiple outcome measures in major depressive disorder: a phase II randomized, placebo-controlled studyNeuropsychopharmacol201136S302S304
   Google Scholar
• ThaseMEYouakimJMSkubanAEfficacy and safety of adjunctive brexpiprazole 2 mg in major depressive disorder: a phase 3, randomized, double-blind study in patients with inadequate response to antidepressantsJ Clin Psychiatry2015761224123126301701
   PubMed Web of Science ®Google Scholar
• ThaseMEYouakimJMSkubanAAdjunctive brexpiprazole 1 and 3 mg for patients with major depressive disorder following inadequate response to antidepressants: a phase 3, randomized, double-blind studyJ Clin Psychiatry2015761232124026301771
   PubMed Web of Science ®Google Scholar
• MontgomerySAAsbergMA new depression scale designed to be sensitive to changeBr J Psychiatry1979134382389444788
   PubMed Web of Science ®Google Scholar
• BermanRMMarcusRNSwaninkRThe efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled studyJ Clin Psychiatry20076884385317592907
   PubMed Web of Science ®Google Scholar
• MarcusRNMcQuadeRDCarsonWHThe efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled studyJ Clin Psychopharmacol20082815616518344725
   PubMed Web of Science ®Google Scholar
• El-KhaliliNJoyceMAtkinsonSExtended-release quetiapine fumarate (quetiapine XR) as adjunctive therapy in major depressive disorder (MDD) in patients with an inadequate response to ongoing antidepressant treatment: a multicenter, randomized, double-blind, placebo-controlled studyInt J Neuropsychopharmacol20101391793220175941
   PubMed Web of Science ®Google Scholar
• NelsonJCSkubanAZhangPLong-term safety of adjunctive brexpiprazole in MDD: results from two 52-week open-label studiesPoster presented at: the 168th annual meeting of the American Psychiatric Association2015Toronto
   Google Scholar